Pharma-Govt Collusion: Trump’s Regeneron Deal Masks Structural Drug Price Crisis, Exacerbating Inequity in U.S. Healthcare
Original framing: “Trump will unveil a deal with Regeneron to lower drug prices - AP News” — AP News (via Google News)
The headline and framing expose a paradox: a populist promise of lower prices that actually reinforces corporate profit, creating an ironic inversion that destabilizes the official narrative. This trickster reading uncovers the absurdity of a deal that masks deeper systemic capture.
The Trump‑Regeneron deal illustrates how a populist veneer can conceal entrenched corporate capture, a paradox highlighted by the trickster dimension.
While the article touches on scientific and marginalised‑voice concerns, it lacks historical depth, cross‑cultural comparison, and artistic‑spiritual framing, limiting its systemic insight. Future modelling and robust policy reforms—such as Medicare price negotiation, patent overhaul, transparent oversight, and community investment—are needed to transform the structural drug‑price crisis into an equitable health ecosystem.